The therapy is generally applied in addressing processes linked to inflammatory or irritative states. This compound may be part of symptomatic management in conditions where symptoms may intensify temporarily, such as diabetic polyneuropathy and alcoholic polyneuropathy. The use of this medication is relevant when supportive symptom management is appropriate in scenarios where additional management of discomfort is required.

It offers symptomatic relief that helps patients cope more steadily with symptoms related to physical discomfort, such as the pain and burning sensations that interfere with daily functioning. The therapy may be part of symptomatic management in patients experiencing symptoms of increased neurological or muscular activity. This approach contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability. The application helps improve day-to-day comfort during symptomatic periods and supports patients during episodes of heightened discomfort.

Quick Fact: Supportive relief for symptoms related to physical discomfort.

Regulatory References

1. NIH StatPearls overview of Alpha-Lipoic Acid

Official Eligibility Profile for Berlithion 300 (Thioctic Acid)

This section defines the populations who are permitted, restricted, or prohibited from using Berlithion 300, based strictly on government regulatory documents.

Classification	Official Regulatory Status
Populations Allowed	Adults aged 18 years and over.
Absolute Contraindication	Individuals with known hypersensitivity to Thioctic Acid or to any of the product's excipients.
Pediatric Use	Treatment is not recommended for children and adolescents due to a lack of clinical experience in this age group.

Conditional Use and Limitations

Use of this medicine is restricted or requires caution in specific populations:

• Pregnancy and Lactation: Use requires a careful benefit/risk assessment by a physician, as human data regarding fetal risk and excretion into breast milk are either inconclusive or unknown.
• Metabolic Conditions: Patients with diabetes mellitus must use the medicine with caution due to the risk of hypoglycemia. Monitoring is required.
• Nutritional Status: Individuals with underlying thiamine deficiency must receive mandatory supplementation before and during treatment.
• Organ Function: Caution and close monitoring are required for patients with hepatic impairment, as clinical experience in this group is limited.

Interactions with other medicines and products

This section outlines interaction patterns for the active substance, alpha-lipoic acid (Thioctic Acid), as officially documented in government regulatory sources. The interaction profile is structured by pharmacodynamic effects and chemical properties.

Category	Officially Documented Interaction Patterns
Pharmacodynamic Reinforcement	Co-administration with insulin or oral antidiabetics may potentiate their blood-sugar lowering effect. This necessitates close monitoring of blood glucose levels and may require a reduction in the dose of the antidiabetic medicine to mitigate risk.
Efficacy-Reducing Interactions	The co-administration of alpha-lipoic acid with Cisplatin leads to a documented loss in the efficacy of Cisplatin. Furthermore, use with Thyroid Hormone products may result in a decrease in the hormone's intended effects.

---

Bioavailability and Substance Restrictions

The regulatory information imposes specific constraints related to timing and substance intake. The bioavailability of the oral formulation is significantly reduced when co-ingested with meals. To ensure proper exposure, a mandatory timing rule requires the medicine be taken on an empty stomach, separated from eating by at least thirty minutes before or two hours after the meal. Regular intake of alcohol is documented as a factor that can impair the overall success of the treatment for neuropathic conditions, and avoidance is therefore advised during therapy. The regulatory profile does not explicitly list interactions mediated by cytochrome P450 enzymes or drug transporters.

The pharmacological action of Berlithion 300 is defined by the dual activity of its active ingredient, Alpha-Lipoic Acid, which functions as an amphiphilic antioxidant and an essential metabolic co-factor. These two mechanisms operate synergistically, resulting in the simultaneous modulation of cellular redox state and enhancement of metabolic flux in nerve tissue.

Reinforcing the Antioxidant Defense System

Berlithion 300 acts as a direct scavenger of Reactive Oxygen Species (ROS) across both the cell's aqueous and lipid compartments. It regenerates the body's own key protective molecules, like Glutathione, by reducing their oxidized forms back to active status. This redox regulation results in the stabilization of neuronal membranes and tissues against oxidative degradation.

Enhancing Cellular Energy and Glucose Metabolism

The drug acts as a necessary co-factor for mitochondrial enzymes, such as the Pyruvate Dehydrogenase Complex ( PDH), which are essential for generating ATP. It also modulates insulin signaling, enhancing cellular glucose uptake and utilization, which increases the availability of substrate for ATP synthesis in neurons. This cascade enhances the rate of neuronal metabolism and contributes to the maintenance of nerve signal transmission dynamics.

Modulation of Inflammatory and Vascular Signaling

Alpha-Lipoic Acid modulates the signaling pathway by inhibiting the activation of the transcription factor NF-kappaB, thereby limiting the downstream release of inflammatory mediators. This effect extends to the vascular lining, where it supports endothelium-dependent vasodilation and improved localized blood flow. This systemic action facilitates improved nutrient and oxygen perfusion of peripheral nerve structures.

Berlithion 300, which contains the active substance alpha-lipoic acid (thioctic acid), is used following a two-phase protocol. The general principle of administration involves an initial period of intensive therapy followed by a transition to a long-term continuation regimen.

Intensive Phase and Administration

The treatment typically begins with the intensive intravenous (IV) route, administered at a standardized dose of 600 mg once per day. The solution concentrate must first be diluted in a compatible infusion solution, such as 0.9% Normal Saline, as part of the preparation requirements. This diluted dose must be delivered as a slow short infusion over a minimum duration of 30 minutes. To protect the photosensitive solution, the product is required to be shielded from light during both preparation and administration. This initial course of IV therapy is typically maintained for a duration of two to four weeks.

Continuation and Oral Use

Upon completion of the IV intensive course, the therapy transitions to the oral route for long-term continuation. The standard oral maintenance dose is 600 mg taken once daily. While individual regimens may vary, standard patterns include taking doses after each main meal during initial loading phases. No specific dose adjustments for populations such as older adults or those with renal or hepatic impairment are explicitly specified.

Research Evidence / Overview of Studies for Berlithion 300

---

Evidence for Use in Managing Diabetic Neuropathy

This section will summarize the available clinical studies, including randomized controlled trials, that have investigated how Berlithion 300 was evaluated in studies related to outcomes related to systemic or functional imbalance in patients with diabetic neuropathy.

Berlithion 300 was studied for its application in conditions characterized by functional limitations and nerve damage caused by diabetes. Research examined patients with this condition, which can involve outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Research monitored outcomes related to symptom intensity or variability, often using scales to track patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in the studies conducted over defined time intervals. Research highlights changes measured during the study period that contribute to understanding symptom patterns in the observed populations. However, the evidence quality varies across studies, and results apply only to the populations studied.

---

Evidence for Use in Treating Alcoholic Polyneuropathy

This part will outline the research conducted where Berlithion 300 was evaluated in research exploring outcomes related to physical discomfort associated with alcoholic polyneuropathy, based on published scientific literature.

Berlithion 300 was evaluated in research contexts involving this specific type of nerve damage. The studies monitored how patients with this condition reported their experience and tracked outcomes monitoring physiological strain or stress. The data so far show patterns related to outcomes related to physical discomfort in some study participants in the studied groups. The research explored short-term symptom changes, and the findings help contextualize how patients reported their experience.

---

What is Still Uncertain About Berlithion 300

This concluding section will synthesize the main evidence gaps and clarify what areas regarding the use of Berlithion 300 still require more scientific research.

One key area of uncertainty is the precise long-term effects, as there is limited information for long-term outcomes. Additionally, findings were mixed in some trials when comparing different doses or different patient subgroups, meaning the data may be inconsistent in specific contexts. Research is ongoing to address these gaps. Currently, the research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Meta-analysis of clinical trials on the efficacy and safety of alpha-lipoic acid in the treatment of diabetic polyneuropathy

Common questions about Берлитион 300 (FAQ)

Q: How does Berlithion 300 interact with iron or magnesium preparations?

Official documents indicate that the active substance, alpha-lipoic acid, can bind to metals. Due to this chemical property, taking the medicine at the same time as preparations containing iron or other metal cations may reduce the efficacy or absorption of those products. Separation of the intake time is typically described in official documents as a method to mitigate this interaction.

Q: Is a special diet required while taking Berlithion 300?

Official instructions highlight a mandatory timing rule related to food intake. The oral form is typically instructed to be taken on an empty stomach to ensure proper absorption, separated from meals by at least 30 minutes before or two hours after.

Additionally, regular consumption of alcohol is documented as a factor that may negatively affect treatment success, and avoidance is described in official documents as advised during therapy.

Q: What is the difference between Berlithion 300 injections and tablets?

The difference lies in their intended phase of therapy. The intravenous (IV) form is designated for the initial, intensive phase of treatment, which typically lasts for a few weeks.

The oral tablet/capsule form is then used for the long-term continuation or maintenance phase of therapy.

Q: How is the safety of Berlithion 300 described for long-term use?

Studies have examined the medicine over defined durations, such as six months. Official regulatory summaries indicate that information regarding the precise long-term effects beyond the studied periods may be limited or uncertain. The official label notes that continuous use requires oversight by a healthcare professional.

Q: Why do neurologists sometimes prescribe Berlithion 300?

The active substance provides neuroprotective and metabolic support for peripheral nerve structures. Official documents describing how the medicine works indicate that this action supports the nervous system and aligns with the management of nerve dysfunction, a focus area for neurologists.

Q: Are there contraindications that are often forgotten?

Official documents list known hypersensitivity to the active substance as an absolute contraindication. Cautions are noted for specific populations, including those with pre-existing thiamine deficiency. Official documents note that pre-existing thiamine deficiency is associated with a requirement for mandatory supplementation.

Q: Can Berlithion 300 affect blood test results?

Yes, the active substance has a documented potential to potentiate the effect of insulin and other blood glucose-lowering agents. This action can lead to low blood sugar (hypoglycemia), and this change in glucose level would be reflected in blood test results.

Q: Is Berlithion 300 compatible with other vitamin complexes?

Official safety notes state that individuals with thiamine deficiency must receive mandatory thiamine supplementation when the medicine is used. However, official regulatory documents do not provide a general statement regarding the compatibility of the drug with all other vitamin complexes.

Q: What should I do if one dose of Berlithion 300 is missed?

Regulatory labels typically state that a double dose should not be taken to compensate for a missed dose. Instead, if it is almost time for the next scheduled dose, the instruction is usually to skip the missed dose and continue with the regular schedule.

Q: What is the official classification of Berlithion 300 (prescription/over-the-counter)?

The active substance, thioctic acid, is available globally in various formulations and strengths. The high-dose therapeutic treatment for neuropathy often carries a prescription status, while lower doses may be marketed as dietary supplements. The intravenous form is always administered in a clinical setting by a health professional.

Q: Why do some people say that Berlithion 300 did not help them?

Clinical trials on the active substance suggest that study findings were mixed in some patient subgroups, and evidence quality can vary across different research projects. This means the therapeutic effect may not be consistent or noticeable for every individual in the population studied.

Q: What is the maximum duration of treatment described in studies?

While typical treatment protocols for neuropathy involve an initial intravenous phase followed by a maintenance phase lasting up to six months, some clinical studies have investigated the use of the oral form for durations up to four years in certain contexts.

Q: Does Berlithion 300 contain lactose or gluten?

The composition of the final product, including non-active ingredients (excipients), is specific to the formulation (tablet/capsule). The presence of excipients such as lactose or gluten in a specific Berlithion 300 product is detailed within the official product information.

Q: Can Berlithion 300 affect blood pressure?

The active substance is documented to support endothelium-dependent vasodilation, which can improve blood flow. Official regulatory labeling in some regions lists low blood pressure (hypotension) as a rare adverse reaction associated with the medication.

Q: What causes the 'pins and needles' feeling after Berlithion 300 injection?

Official safety documents do not specifically list 'pins and needles' (paresthesia) as a common adverse reaction related to the injection. However, some regulatory labels list feelings of dizziness or being light-headed as possible adverse effects that may be associated with the intravenous administration.

Q: What does the term 'metabolic preparation' mean?

The active substance functions as an essential metabolic co-factor for key enzymes in the body. This means it supports cellular energy production by helping convert glucose into ATP, thereby supporting the overall rate of neuronal metabolism (cell energy processes in the nerves).

Q: What is the likelihood of developing hypoglycemia when taking Berlithion 300?

Low blood sugar (Hypoglycemia) is a documented adverse reaction, especially when the medicine is used concurrently with antidiabetic treatments. Official labeling indicates this reaction is typically classified as Rare or Uncommon. Official safety notes state that patients with diabetes require close blood sugar monitoring when taking the medicine.

How to Store and Dispose of Berlithion 300

The storage and disposal requirements for Berlithion 300 (Thioctic Acid) are strictly defined by regulatory documents to maintain product integrity and safety.

️ Storage Requirements

Constraint	Requirement as per Official Labeling
Temperature	Store at a temperature not exceeding 25 °C (Store below 25 °C).
Protection	Must be protected from light and moisture; do not freeze the liquid solution.
Packaging	Keep the medicine in its original container and ensure the container remains tightly closed.
Child Safety	Mandatory to keep the product out of the sight and reach of children.
Stability	Any prepared or diluted IV solution must be used immediately (immediate-use stability).

️ Disposal Instructions

Regulatory instructions mandate that unused or expired Berlithion 300 must be discarded according to local regulations. The product must not be thrown away into household waste or poured into wastewater to prevent environmental contamination.